About KRYSTAL BIOTECH, INC.
Krystal Biotech, Inc. is a commercial-stage company developing genetic medicines for high unmet medical needs, focusing on redosable gene therapies for severe, life-threatening, or rare diseases. Their first commercial product, VYJUVEK®, is the first and only redosable gene therapy for the treatment of dystrophic epidermolysis bullosa.
Development of genetic medicines using a clinically-proven platform based on a modified and engineered HSV-1 vectorAdvancing an integrated pipeline of genetic therapies to correct the root cause of serious and rare diseasesManufacturing with two GMP facilities
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to KRYSTAL BIOTECH, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.